In primary Sjögren’s syndrome (pSS), anti-Ro52 antibodies are detected in up to 60% of patients and are significantly associated with disease activity, salivary gland dysfunction, vasculitis, and interstitial lung disease (ILD). This evidence concerns the gene TRIM21 and interstitial lung disease.